{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-204999","form_type":"8-K","ticker":"OFIX","cik":"0000884624","company_name":"Orthofix Medical Inc.","filed_at":"2026-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.867840+00:00","generated_at":"2026-05-14T23:43:15.024946+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Orthofix Q1 pro forma revenue $196.4M +2.7% constant currency; reaffirms FY guidance","bullets":["GAAP net loss $(20.9)M vs $(53.1)M prior year; adjusted EBITDA $9.7M (4.9% of pro forma sales) vs $11.4M (6.0%) prior year.","Global Spine Fixation +6%, Therapeutic Solutions +5%, Limb Reconstruction +10% reported (+3% constant currency).","Reaffirms FY2026 net sales $850M-$860M, adjusted EBITDA $95M-$98M, positive free cash flow.","Cash $120.9M at March 31, 2026; plans to repay $424M 0.875% exchangeable notes due June 2026.","Distributor transitions largely behind; expects improved commercial execution and product launches later in 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-204999","json":"https://secwatch.observer/filing/0001193125-26-204999.json","markdown":"https://secwatch.observer/filing/0001193125-26-204999.md","text":"https://secwatch.observer/filing/0001193125-26-204999.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/884624/000119312526204999/0001193125-26-204999-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/884624/000119312526204999/ofix-20260505.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T23:43:15.024946+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a5379e600572296edcaf098ea718d7b8acfa9f29","claim":"Orthofix Medical Inc. reported the first quarter ended March 31, 2026 results: revenue $196.7 million, net income $(20.9) million, EPS $(0.52) per share. Guidance reaffirmed.","evidence_excerpt":"measures contained within this release exclude the impact of the Company’s decision to discontinue its M6TM product lines. Highlights • First quarter 2026 reported net sales of $196.7 million, including sales from M6 artificial cervical and lumbar discs. Non-GAAP pro forma net sales of $196.4 million, excluding sales from M6 discs, increased 3% year over year on a","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/884624/000119312526204999/0001193125-26-204999-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2026"},{"label":"Revenue","value":"$196.7 million"},{"label":"Net income","value":"$(20.9) million"},{"label":"EPS","value":"$(0.52) per share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}